Overview

• The WHO’s updated guidelines officially endorse lenacapavir administered every six months as an alternative to daily oral PrEP and existing injectables
• PURPOSE 1 and 2 clinical trials reported nearly 100% efficacy in preventing HIV infection, forming the evidence base for the recommendation
• Treatment guidance now incorporates dual therapy with dolutegravir and lamivudine for individuals maintaining undetectable viral loads
• Gilead Sciences and the Global Fund secured voluntary licensing agreements to supply affordable lenacapavir in 120 low- and middle-income countries
• Advocates caution that budget shortfalls and operational barriers could hinder rollout without increased donor and government commitment